AU2002217020A1 - Method for screening anti-proliferative compounds and inhibiting tumor growth - Google Patents

Method for screening anti-proliferative compounds and inhibiting tumor growth

Info

Publication number
AU2002217020A1
AU2002217020A1 AU2002217020A AU1702002A AU2002217020A1 AU 2002217020 A1 AU2002217020 A1 AU 2002217020A1 AU 2002217020 A AU2002217020 A AU 2002217020A AU 1702002 A AU1702002 A AU 1702002A AU 2002217020 A1 AU2002217020 A1 AU 2002217020A1
Authority
AU
Australia
Prior art keywords
tumor growth
inhibiting tumor
screening anti
proliferative compounds
proliferative
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002217020A
Inventor
Penny Elisabeth Phillips
Patrick Andre Schindler
Harry Towbin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Publication of AU2002217020A1 publication Critical patent/AU2002217020A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6806—Determination of free amino acids
    • G01N33/6812—Assays for specific amino acids
    • G01N33/6815—Assays for specific amino acids containing sulfur, e.g. cysteine, cystine, methionine, homocysteine

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Food Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
AU2002217020A 2000-11-14 2001-11-12 Method for screening anti-proliferative compounds and inhibiting tumor growth Abandoned AU2002217020A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US24848900P 2000-11-14 2000-11-14
US60/248,489 2000-11-14
PCT/EP2001/013076 WO2002039990A2 (en) 2000-11-14 2001-11-12 Method for screening anti-proliferative compounds and inhibiting tumor growth

Publications (1)

Publication Number Publication Date
AU2002217020A1 true AU2002217020A1 (en) 2002-05-27

Family

ID=22939368

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002217020A Abandoned AU2002217020A1 (en) 2000-11-14 2001-11-12 Method for screening anti-proliferative compounds and inhibiting tumor growth

Country Status (4)

Country Link
EP (1) EP1337854A2 (en)
JP (1) JP2004514122A (en)
AU (1) AU2002217020A1 (en)
WO (1) WO2002039990A2 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005014574A1 (en) * 2003-07-25 2005-02-17 Novartis Ag Substituted lactams and their use as anti-cancer agents
US7153846B2 (en) 2003-10-24 2006-12-26 Sanofi-Aventis Deutschland Gmbh Bengamide derivatives, process for preparing them, and their use
FR2878528B1 (en) * 2004-11-29 2008-05-16 Aventis Pharma Sa 2-ALCOXY-3,4,5-TRIHYDROXY-ALKYLAMIDES, PREPARATION THEREOF, COMPOSITIONS CONTAINING SAME AND USE THEREOF
FR2878525B1 (en) 2004-11-29 2007-02-23 Aventis Pharma Sa BENGAMIDES HAVING SUBSTITUTED CAPROLACTAM CYCLE, PREPARATION METHOD, COMPOSITIONS CONTAINING SAME AND USE THEREOF
FR2901556A1 (en) 2006-05-24 2007-11-30 Sanofi Aventis Sa 2-ALCOXY-3,4,5-TRIHYDROXY-ALKYLAMIDE DERIVATIVES, THEIR PREPARATION, COMPOSITIONS CONTAINING SAME AND USE THEREOF
FR2901555A1 (en) 2006-05-24 2007-11-30 Sanofi Aventis Sa 2-ALCOXY-3,4,5-TRIHYDROXY-ALKYLAMIDE-BENZOTHIAZEPINE, THEIR PREPARATION, COMPOSITIONS CONTAINING SAME AND USE THEREOF
FR2901554B1 (en) 2006-05-24 2011-04-01 Sanofi Aventis 2-ALCOXY-3,4,5-TRIHYDROXY-ALKYLAMIDE-BENZAZEPINE, PREPARATION THEREOF, COMPOSITIONS CONTAINING SAME AND USE THEREOF
FR2926463B1 (en) * 2008-01-22 2010-08-13 Centre Nat Rech Scient USE OF AMINOPEPTIDASE INHIBITORS OR AZAINDOLE COMPOUNDS FOR PREVENTING OR TREATING CANCER METASTASES OF EPITHELIAL ORIGIN
ES2402564T3 (en) * 2008-11-06 2013-05-06 Merck Patent Gmbh Use of EEF1A as a biomarker for screening METAP2 inhibitors

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998056372A1 (en) * 1997-06-09 1998-12-17 Massachusetts Institute Of Technology TYPE 2 METHIONINE AMINOPEPTIDASE (MetAP2) INHIBITORS AND USES THEROF

Also Published As

Publication number Publication date
WO2002039990A3 (en) 2003-03-13
JP2004514122A (en) 2004-05-13
EP1337854A2 (en) 2003-08-27
WO2002039990A2 (en) 2002-05-23

Similar Documents

Publication Publication Date Title
AU3495799A (en) A method for inhibiting tumor invasion or spreading in a subject
AU7472198A (en) Method for limiting the growth of microorganisms using metal-containing compounds
AU2777999A (en) Method for treating plants
AUPQ533700A0 (en) Soil treatment method
EP1469316A2 (en) Screening method
HUP0201142A2 (en) Compound screening method
AUPR152100A0 (en) Method for treating coral
IL149148A0 (en) Method for preventing dyskinesias
AU2001232263A1 (en) Method of treating seeds
AU2002217020A1 (en) Method for screening anti-proliferative compounds and inhibiting tumor growth
AU7441000A (en) A method for preparing and screening one or more compounds
HUP0201804A2 (en) Method for preventing tumoral growth
AU2002335993A1 (en) Method for land improvement and microorganisms therefor
AU1553101A (en) Screening method
GB0009363D0 (en) Compound screening method
AU6429000A (en) Screening method
GB2359358B (en) Compound screening method
AU2001243297A1 (en) Method for treating or preventing depression
AU2872501A (en) Screening method
AU4856501A (en) Screening method for compounds
AU5186999A (en) Soil treatment method
AU2000224577A1 (en) Screening method
WO2001053458A9 (en) Methods and reagents for performing antimicrobial compound screening
AU2001288116A1 (en) Screening method
AU2002220868A1 (en) Screening method